Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has received a consensus rating of “Buy” from the ten brokerages that are presently covering the stock, MarketBeat reports. Ten analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $43.43.
Several research firms have weighed in on SYRE. Evercore ISI began coverage on shares of Spyre Therapeutics in a research note on Tuesday, July 16th. They issued an “outperform” rating for the company. Wedbush began coverage on shares of Spyre Therapeutics in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $45.00 price target for the company.
Check Out Our Latest Stock Analysis on SYRE
Hedge Funds Weigh In On Spyre Therapeutics
Spyre Therapeutics Stock Up 5.0 %
Spyre Therapeutics stock opened at $30.40 on Friday. The company has a market capitalization of $1.22 billion, a PE ratio of -0.43 and a beta of 2.92. The firm has a fifty day simple moving average of $27.94 and a two-hundred day simple moving average of $32.03. Spyre Therapeutics has a twelve month low of $8.43 and a twelve month high of $47.97.
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.04. As a group, equities analysts expect that Spyre Therapeutics will post -3.68 earnings per share for the current fiscal year.
About Spyre Therapeutics
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Featured Articles
- Five stocks we like better than Spyre Therapeutics
- Stock Splits, Do They Really Impact Investors?
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- The How and Why of Investing in Gold Stocks
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- How to invest in marijuana stocks in 7 steps
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.